North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

January 2020 | 105 pages | ID: N366D21B5407EN
GMD Research

Abstracts

North America human insulin market is expected to reach $23.52 billion by 2025, growing by 7.36% annually over the next years.

Highlighted with 27 tables and 52 figures, this 105-page report “North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify North America human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.

Based on product type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Human Insulin Drugs
• Human Insulin Delivery Devices

Based on product, the North America Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)
• Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)

Based on product, the North America Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Syringes
• Pens (further segmented into Disposable, Reusable, Pen needles)
• Pumps
• Others

Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes and Prediabetes

Based on distribution channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Geographically, the following national/local markets are fully investigated:

• U.S.
• Canada

For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in North America human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players:

Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt
(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF NORTH AMERICA MARKET BY PRODUCT TYPE

3.1 Market Overview by Product Type
3.2 Human Insulin Drugs
3.3 Human Insulin Delivery Devices

4 SEGMENTATION OF NORTH AMERICA HUMAN INSULIN DRUGS MARKET BY DRUG PRODUCT

4.1 Market Overview by Drug Product
4.2 Modern Human Insulin
  4.2.1 Modern Human Insulin by Type
  4.2.2 Modern Human Insulin by Brand
4.3 Traditional Human Insulin
  4.3.1 Traditional Human Insulin by Type
  4.3.2 Traditional Human Insulin by Brand

5 SEGMENTATION OF NORTH AMERICA HUMAN INSULIN DELIVERY DEVICES MARKET BY DEVICE PRODUCT

5.1 Market Overview by Product
5.2 Syringes
5.3 Pens
5.4 Pumps
5.5 Other Devices

6 SEGMENTATION OF NORTH AMERICA MARKET BY APPLICATION

6.1 Market Overview by Application
6.2 Type 1 Diabetes
6.3 Type 2 Diabetes
6.4 Gestational Diabetes and Prediabetes

7 SEGMENTATION OF NORTH AMERICA MARKET BY DISTRIBUTION CHANNEL

7.1 Market Overview by Distribution Channel
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies

8 NORTH AMERICA MARKET 2019-2026 BY COUNTRY

8.1 Overview of North America Market
8.2 U.S. Market
8.3 Canadian Market

9 COMPETITIVE LANDSCAPE

9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt

10 INVESTING IN NORTH AMERICA MARKET: RISK ASSESSMENT AND MANAGEMENT

10.1 Risk Evaluation of North America Market
10.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of North America Human Insulin Market, 2019-2026
Table 2. Main Product Trends and Market Opportunities in North America Human Insulin Market
Table 3. North America Human Insulin Market by Product Type, 2019-2026, $ mn
Table 4. North America Human Insulin Drugs Market by Product, 2019-2026, $ mn
Table 5. North America Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, $ mn
Table 6. North America Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, $ mn
Table 7. North America Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, $ mn
Table 8. North America Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, $ mn
Table 9. North America Human Insulin Delivery Devices Market by Product, 2019-2026, $ mn
Table 10. North America Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, $ mn
Table 11. North America Human Insulin Market by Application, 2019-2026, $ mn
Table 12. North America Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 13. North America Human Insulin Market by Country, 2019-2026, $ mn
Table 14. U.S. Human Insulin Market by Product Type, 2019-2026, $ mn
Table 15. U.S. Human Insulin Market by Application, 2019-2026, $ mn
Table 16. U.S. Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 17. Canada Human Insulin Market by Product Type, 2019-2026, $ mn
Table 18. Canada Human Insulin Market by Application, 2019-2026, $ mn
Table 19. Canada Human Insulin Market by Distribution Channel, 2019-2026, $ mn
Table 20. North America Human Insulin Market by Key Vendor, 2019, $ mn
Table 21. Astra Zeneca PLC: Company Snapshot
Table 22. Astra Zeneca PLC: Business Segmentation
Table 23. Astra Zeneca PLC: Product Portfolio
Table 24. Astra Zeneca PLC: Revenue, 2016-2018, $ mn
Table 25. Astra Zeneca PLC: Recent Developments
Table 26. Risk Evaluation for Investing in North America Market, 2019-2026
Table 27. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026
Figure 4. North America Human Insulin Market, 2019-2026, $ mn
Figure 5. Primary Drivers and Impact Factors of North America Human Insulin Market
Figure 6. Primary Restraints and Impact Factors of North America Human Insulin Market
Figure 7. Porter’s Fiver Forces Analysis of North America Human Insulin Market
Figure 8. Breakdown of North America Human Insulin Market by Product Type, 2019-2026, % of Revenue
Figure 9. Contribution to North America 2020-2026 Cumulative Revenue by Product Type, Value ($ mn) and Share (%)
Figure 10. North America Human Insulin Market: Human Insulin Drugs, 2019-2026, $ mn
Figure 11. North America Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, $ mn
Figure 12. Breakdown of North America Human Insulin Drugs Market by Product, 2019-2026, % of Revenue
Figure 13. Contribution to North America Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)
Figure 14. North America Human Insulin Market: Modern Human Insulin, 2019-2026, $ mn
Figure 15. North America Modern Human Insulin Market: Long-acting, 2019-2026, $ mn
Figure 16. North America Modern Human Insulin Market: Rapid- acting, 2019-2026, $ mn
Figure 17. North America Modern Human Insulin Market: Premixed, 2019-2026, $ mn
Figure 18. North America Modern Human Insulin Market: Lantus, 2019-2026, $ mn
Figure 19. North America Modern Human Insulin Market: Apidra, 2019-2026, $ mn
Figure 20. North America Modern Human Insulin Market: Levemir, 2019-2026, $ mn
Figure 21. North America Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, $ mn
Figure 22. North America Modern Human Insulin Market: Novomix, 2019-2026, $ mn
Figure 23. North America Modern Human Insulin Market: Humalog, 2019-2026, $ mn
Figure 24. North America Modern Human Insulin Market: Other Brands, 2019-2026, $ mn
Figure 25. North America Human Insulin Market: Traditional Human Insulin, 2019-2026, $ mn
Figure 26. North America Traditional Human Insulin Market: Short-acting, 2019-2026, $ mn
Figure 27. North America Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, $ mn
Figure 28. North America Traditional Human Insulin Market: Premixed, 2019-2026, $ mn
Figure 29. North America Traditional Human Insulin Market: Humulin, 2019-2026, $ mn
Figure 30. North America Traditional Human Insulin Market: Insuman, 2019-2026, $ mn
Figure 31. North America Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, $ mn
Figure 32. Breakdown of North America Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue
Figure 33. Contribution to North America Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)
Figure 34. North America Human Insulin Delivery Devices Market: Syringes, 2019-2026, $ mn
Figure 35. North America Human Insulin Delivery Devices Market: Pens, 2019-2026, $ mn
Figure 36. North America Human Insulin Delivery Devices Market: Pumps, 2019-2026, $ mn
Figure 37. North America Human Insulin Delivery Devices Market: Other Devices, 2019-2026, $ mn
Figure 38. Breakdown of North America Human Insulin Market by Application, 2019-2026, % of Revenue
Figure 39. Contribution to North America 2020-2026 Cumulative Revenue by Application, Value ($ mn) and Share (%)
Figure 40. North America Human Insulin Market: Type 1 Diabetes, 2019-2026, $ mn
Figure 41. North America Human Insulin Market: Type 2 Diabetes, 2019-2026, $ mn
Figure 42. North America Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, $ mn
Figure 43. Breakdown of North America Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue
Figure 44. Contribution to North America 2020-2026 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)
Figure 45. North America Human Insulin Market: Hospital Pharmacies, 2019-2026, $ mn
Figure 46. North America Human Insulin Market: Retail Pharmacies, 2019-2026, $ mn
Figure 47. North America Human Insulin Market: Online Pharmacies, 2019-2026, $ mn
Figure 48. Breakdown of North America Human Insulin Market by Country, 2019 and 2026, % of Revenue
Figure 49. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 50. U.S. Human Insulin Market, 2019-2026, $ mn
Figure 51. Canada Human Insulin Market, 2019-2026, $ mn
Figure 52. Growth Stage of North America Human Insulin Industry over the Forecast Period